Financial Data and Key Metrics Changes - The company generated revenue of $164 million in Q1 2024, a 28% increase compared to $127.9 million in Q1 2023 [5][11] - US revenue was $155.8 million, reflecting a 25% increase from $124.5 million in the prior year [11] - Revenue outside the US increased by 141% to $8.2 million, primarily due to a rebound in Europe, especially in Germany [6][11] - The net loss for Q1 2024 was $10 million, an improvement from a net loss of $15.4 million in Q1 2023, resulting in a net loss per share of $0.34 compared to $0.53 [6][11] - The company expects full-year revenue guidance to be between $783 million and $793 million, representing a growth of 25% to 27% over 2023 [12] Business Line Data and Key Metrics Changes - The company expanded its market presence by opening 66 new implanting centers and 11 new sales territories in the US [5] - The gross margin for Q1 2024 was 84.9%, up from 84.4% in the prior year, driven by improved manufacturing efficiencies [11] Market Data and Key Metrics Changes - The company noted a strong rebound in Europe, particularly in Germany, following the derogation received late in Q4 2023 [6] - The SURMOUNT-OSA trial results suggest that GLP-1s may complement the company's market opportunity by enabling more patients to qualify for Inspire therapy [7] Company Strategy and Development Direction - The company remains focused on increasing therapy adoption and expanding its market presence while enhancing its technology [10] - The company plans to continue its growth strategy by increasing utilization at existing centers and opening new centers [10] - The Inspire V submission is under FDA review, with a soft launch expected in 2024 and a full launch in 2025 [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum and the ability to increase guidance based on strong demand and utilization trends [12] - The company anticipates being profitable for the full year 2024, with diluted net income per share guidance of $0.10 to $0.20 [12] Other Important Information - The company has invested heavily in research and development, commercial infrastructure, and direct-to-consumer campaigns to drive awareness and adoption of Inspire therapy [10] - The company has built a strong clinical evidence base with nearly 6,000 patients worldwide and over 280 peer-reviewed publications [8] Q&A Session Summary Question: US performance and growth dynamics - Management acknowledged strong Q1 growth but noted it was below expectations, attributing some dynamics to Medicare versus private pay mix and tracking documentation requirements with UnitedHealthcare [14][15] Question: Confidence in raised guidance - Management indicated that the raised guidance is based on strong performance in Europe and confidence in US growth, particularly in the latter half of the year [17][27] Question: Utilization trends and metrics reporting - Management discussed ongoing focus on utilization and indicated a shift towards reporting revenue and profitability metrics rather than center and territory metrics starting in 2025 [18][21] Question: Impact of SURMOUNT-OSA on patient funnel - Management noted that discussions around GLP-1s could lead to more patients qualifying for Inspire therapy, with positive reports from the field [30][31] Question: Updates on pediatric population and high BMI patients - Management reported progress in treating high AHI patients and opening additional children's hospitals to increase awareness and treatment options [34][35] Question: Profitability drivers and DTC strategy - Management highlighted targeted digital advertising as a key component of their DTC strategy, with a focus on improving conversion rates while maintaining flat spending compared to 2023 [38][75] Question: Inspire V launch timing and potential patient delays - Management confirmed that the Inspire V launch timeline remains on track and does not anticipate significant delays in treatment due to awareness of the new product [41][52] Question: Coverage policy updates for higher BMI patients - Management is actively communicating with payers to update policies in line with FDA approvals, expecting most changes to be implemented by the end of the year [62][63]

Inspire Medical Systems (INSP) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 46.03%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.04 per share when it actually produced earnings of $0.49, delivering a surprise of 1,32 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 ______________________________ Inspire ...

Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2024 Financial Results and Updates 2024 Outlook Inspire Reports Year-over-Year Revenue Growth of 28% in the First Quarter and Expects Profitability for the Full Year 2024 MINNEAPOLIS, Minnesota - May 7, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported f ...

Inspire Reports Year-over-YearRevenue Growth of 28% in the First Quarter and Expects Profitability for the Full Year 2024 MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2024. Recent Business Highlights Generated revenue of $164.0  ...

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024. Inspire is scheduled to present at 7:20 p.m. Eastern Time. The presentation will be accessible via a live webcast ...

Inspire Medical Systems, Inc. (INSP) has been gaining from its focus on research and development (R&D). The optimism led by a solid fourth-quarter 2023 performance and its global presence are expected to contribute further. However, concerns regarding overdependence on the Inspire system and a competitive landscape prevail.Over the past year, this Zacks Rank #1 (Strong Buy) stock has lost 8.1% compared with the 21.8% decline of the industry. The S&P 500 has witnessed 21.7% growth in the said time frame.The ...

Inspire Medical Systems (INSP) shares rallied 9.9% in the last trading session to close at $243.51. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 8.4% gain over the past four weeks.Shares of the company surged likely in anticipation of improved earnings for its first quarter results scheduled to release on May 07, 2024. Loss estimates for the first quarter have narrowed in the past 30 days.This maker of dev ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Surmodics, Inc. (SRDX) : This medical device coating technology provider has seen the Zacks Consensus Estimate for its current year earnings increasing 10.9% over the last 60 days.United States Steel Corporation (X) : This steel manufacturing company has seen the Zacks Consensus Estimate for its current year earnings increasing 17.2% over the last 60 days.Telenor ASA (TELNY) : This telecommunication company has seen the Zacks Consensus ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 Inspire Medical Systems, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...